A novel, first in class, potent, orally bioavailable, brain-penetrant, 11βHSD1 inhibitor1
• Differentiated mechanism of action: blocking cortisol production in the brain
• Symptomatic and disease modifying effects in vivo1
• Well-tolerated – dosed >100 patients/subjects: acceptable clinical safety, toxicity and PK/PD profile1
• Effective human brain concentrations demonstrated1
• XanADu – phase II clinical study underway, dosing subjects with mild AD dementia in USA, UK, AU
• Planning ongoing for additional clinical indications
• Composition of matter IP coverage ≥ 2031, patents granted in all major markets
• XanADu Alzheimer's trial fully funded following completion of ~A$5.3 million capital raise in November 2017
• A range of additional studies adequately funded following completion of ~$17 million capital raising in May 2018
Just happy they have such a strong cash position, $17m +
Boston effect...., page-57
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.50M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.6¢ | 2.5¢ | $5.461K | 215.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 2547818 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 889267 | 5 |
View Market Depth
| Last trade - 10.27am 20/08/2024 (20 minute delay) ? |
| ACW (ASX) Chart |